Industry News

• FDA postpones Oncologic Drugs Advisory Committee meeting to review pixantrone  Cell Therapeutics announced that the FDA informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application.
  Cell Therapeutics, Inc. February 09, 2010  
• Denosumab demonstrated superiority over Zometa(R) in pivotal Phase 3 head-to-head trial  Amgen announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints.
  Amgen February 08, 2010  
• Tyson Foods announces quarterly dividend  The Board of Directors of Tyson Foods, at a meeting on February 4, 2010, declared the quarterly dividend of $.04 per share on Class A common stock and $.036 per share on Class B common stock, payable on June 15, 2010 to shareholders of record at the close of business on June 1, 2010.
  Tyson Foods, Inc. February 08, 2010  
• Pfizer and Keas partner to help consumers take a active role in health care  Pfizer and Keas announced they have entered into an alliance to collaborate on the Keas platform to enable Health and Wellness experts to author, sell and distribute personalized online Care Plans directly to patients.
  Pfizer February 08, 2010  
• Abbott submits new automated ovarian cancer test for U.S. approval  A new diagnostic tool physicians can use to monitor patients for the most common form of ovarian cancer may soon be available in the U.S. Abbott’s ARCHITECT HE4 assay uses a simple blood test to help in monitoring for the recurrence or progression of epithelial ovarian cancer.
  Abbott February 08, 2010  
• MDRNA reports positive results for Its proprietary siRNA delivery technology  MDRNA announced that its lead delivery system formulation demonstrated exceptional stability over a one year period under a variety of conditions. The DiLA2 formulation maintained in vivo knockdown activity with no observed loss in potency over the course of the year-long study.
  MDRNA, Inc. February 08, 2010  
• ALK-Abelló announces disease-modifying effect of GRAZAX® verified  ALK announces positive results from the second follow-up year in a long-term study (GT-08) with GRAZAX®, the company's grass allergy immunotherapy tablet. The results verify that the disease-modifying effect of GRAZAX® is sustained after completion of the recommended three-year treatment regimen.
  ALK-Abelló February 08, 2010  
• Racial dispartities persist in breast, colon cancer cases in U.S.  The incidence of advanced breast cancer diagnosis among black women remained 30 percent to 90 percent higher compared to white women between 1992 and 2004, according to new findings by researchers at Fred Hutchinson Cancer Research Center.
  Fred Hutchinson Cancer Research Center February 08, 2010  
• MDRNA receives compliance extension from NASDAQ  MDRNA announced that it received a letter from NASDAQ Stock Market notifying the Company that it has a grace period of 180 days from its initial notice of non-compliance in which to regain compliance with the $50 million minimum Market Value of Listed Securities for continued listing on the NASDAQ.
  MDRNA, Inc. February 08, 2010  
• Tyson reports first quarter fiscal 2010 results  First quarter 2010 Net EPS was $0.42, a record for a first fiscal quarter, as compared to $(0.27) last year. All operating segments were profitable, with three above their normalized ranges.
  Tyson Foods, Inc. February 05, 2010  

   (next 10 articles)